Navigation Links
Peter J. McGuire, MB BCh, is awarded the 2008-2009 Genzyme/ACMGF Clinical Genetics Fellowship
Date:4/2/2008

Peter J. McGuire, MB BCh, of Mount Sinai Medical Center, New York was honored as the 2008-2009 recipient of the Genzyme/ACMGF Clinical Genetics Fellowship in Biochemical Genetics at the ACMG 2008 Annual Clinical Genetics Meeting in Phoenix, AZ.

The objective of the Genzyme/ACMGF Award is to support a national fellowship program to encourage the recruitment and training of clinicians in the field of clinical biochemical genetics and especially in the diagnosis, management and treatment of individuals with metabolic diseases. This award grants $75,000 per year and will provide for the sponsorship of a trainees first year of fellowship following residency in a genetics fellowship on biochemical genetic diseases.

The Genzyme/ACMGF Clinical Genetics Fellowship in Biochemical Genetics is especially important at this point in history as we work together to increase the genetics workforce and to advance education, research and standards of practice in medical genetics in the United States. said R. Rodney Howell, MD, FACMG, president of the ACMGF.


'/>"/>

Contact: Kathy Ridgely Beal
kbeal@acmg.net
301-238-4582
American College of Medical Genetics
Source:Eurekalert

0

GOOD

Page: 1

Related biology news :

1. Harold Mooney and Peter Raven, winners of the BBVA Foundation Award for Conservation Biology
2. UM coral scientist Peter Glynn wins award for scholarly activity
3. 12 McGill researchers awarded Canada Research Chairs
4. Anthony S. Fauci awarded Lasker Award for Public Service
5. ETH Zurich professor Ari Helenius awarded Benoist Prize
6. Nanobiosym awarded $2 million DTRA contract
7. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
8. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
9. $2.7 million awarded for metastatic colon cancer research
10. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
11. BIO-key(R) and Tiger IT Awarded a Follow-on Contract for Nationwide Voter / Citizen Registration in Bangladesh

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... Conn.Researchers at Yale University have develope...y,s immune response to HIV and HIV-infected cells,...gs, published online in the Journal of the Americ...tic approaches for these diseases. , The molecu...g HIV" (ARM-H) and "antibody-recruiting molecule t...
(Date:11/4/2009)...(top news in natural science) , United States ... less water today than it did 35 years ago, despit...ter use are partly attributable to alternative coo...rigation systems. According to the latest USGS wat...e United States goes to cooling thermoelectric pow...
(Date:11/4/2009)... BC - Lowly bacteria, it turns out, hold the power...ants around the world clean up toxic waste on test...cally RDX, were invented back in World War II and ... These high-energy compounds are often used to pro...on of TNT. , But with increased knowledge of t...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 1China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 2China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 3VIDEO from Medialink and CIGNA 3A Dont Stress Out Over Stress Some of it is Good for You 58857 1VIDEO from Medialink and CIGNA 3A Dont Stress Out Over Stress Some of it is Good for You 58857 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 1Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 4
...nable part of the world,s energy future, especiall...ly abandoned or degraded agricultural lands, repor...nford University. Using these lands for energy cro...earing new land, avoids competition with food prod... to mitigate climate change. Sustainable bioenergy...
...ite near Pulborough, West Sussex, has thrown remar...ast Neanderthals. It provides a snapshot of a thri...es on the verge of extinction. , "The tools we,ve...d potentially older than tools in Britain belongin...ew Pope of Archaeology South East based at the UCL...
...Foundation for the Advancement of Military Medicin...he Health Sciences (USU) are holding the first-eve...researchers and clinicians to discuss current and ...WHAT: USU-HJF Symposium, Experts in their respecti...reaking work being undertaken within the DoD medic...
Other Biology News:Abandoned farmlands are key to sustainable bioenergy 2Britain's last Neanderthals were more sophisticated than we thought 2
(Date:11/6/2009)... 6 BioSpecifics Technolo...ompany developing first-in-class collagenase-based...or the third quarter ended September 30, 2009. ,... this year, the FDA,s Arthritis Advisory Committee...pproval of XIAFLEX(TM) for the treatment of Dupuyt...
(Date:11/6/2009)...., Nov. 6 Calbiotech, Inc. announc... Innovative Research (SBIR) Phase I contract by th... Under terms of the agreement, Calbiotech will dev...nosis of Dengue virus. ,, Dengue virus is a ...hreat to military forces deployed to tropical area...
(Date:11/5/2009)...ov. 5 GenVec, Inc. (Nasd...for the third quarter ended September 30, 2009. Ge...r share) for the three months ended September 30, ... per share) in the comparable quarter of 2008. For...s net loss was $14.1 million ($0.15 per share), co...
(Date:11/5/2009)...hursday, November 5, 2009 at 4:30 p.m. Eastern Tim...ire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (...ay reported unaudited financial results for the th...09 and reviewed the Company,s highlights for the t...ated results reflect the operations of OncoGenex T...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...he,state stem cell agency by California,s Controll...t created the agency, Consumer Watchdog said today...iang found that with a,relatively minor exception ... (CIRM) complies with the requirements of Proposit... they relate to conflict-of-interest,policies, gra...
...of Financing for $3 Million, PITTSBURGH, May 12 ...athology, Inc.,s PathFinderTG(R) have fueled the,c...of-the-art headquarters,in Pittsburgh and the grow..., up from 20 a year ago. Against this backdrop, th...sider round of financing for $3 million. The,proce...
...Pink Sheets: MEDQ), the largest Medical Transcript...riday, May 9th, filed its Form 10-Q quarterly,repo...n for the quarter,ended March 31, 2008., Revenue ...with $89.1M,in the first quarter of 2007. The decr... period was primarily due to customer losses exper...
Other Biology Technology:Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws 2Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws 3Expansion and Relocation to New, State-Of-The-Art Facilities Marks Milestone in Effort to Roll Out New Tool for Cancer Diagnosis 2Expansion and Relocation to New, State-Of-The-Art Facilities Marks Milestone in Effort to Roll Out New Tool for Cancer Diagnosis 3MedQuist Reports First Quarter 2008 Results 2MedQuist Reports First Quarter 2008 Results 3MedQuist Reports First Quarter 2008 Results 4MedQuist Reports First Quarter 2008 Results 5MedQuist Reports First Quarter 2008 Results 6MedQuist Reports First Quarter 2008 Results 7MedQuist Reports First Quarter 2008 Results 8MedQuist Reports First Quarter 2008 Results 9
GIBCO BGJb Medium (Fitton-Jackson Modification) (1X) liquid from Invitrogen
11(R)-HETE from Cayman Chemical
Rabbit Anti-T-box 6 Monoclonal Antibody, Unconjugated, Clone PADZMD.501 from Invitrogen
Rat Anti-karyopherin alpha2 Monoclonal Antibody, Unconjugated, Clone 2G7 from Santa Cruz Biotechnology, Inc.
Biology Products: